<DOC>
	<DOCNO>NCT00110799</DOCNO>
	<brief_summary>SB497115 oral agent activate thrombopoietin receptor increase platelet count healthy volunteer . This study examine several different dos SB497115 treatment patient chronic hepatitis C-related thrombocytopenia potential candidate antiviral treatment pegylated interferon ribavirin . The study conduct two phase , Parts 1 2 . In Part 1 , study subject randomize 4 week SB-497115-GR placebo administer daily without antiviral therapy . Subjects successfully complete Part 1 ( platelet count 70,000/µL Pegasys platelet count 100,000/µL PEG-Intron ) proceed Part 2 . In Part 2 , subject receive additional 8 week SB-497115-GR placebo administer daily antiviral therapy .</brief_summary>
	<brief_title>SB497115 ( Oral Thrombopoietin Receptor Agonist ) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C</brief_title>
	<detailed_description>A Double-Blind , Randomized , Placebo-Controlled , Multi-Centre , Dose-Ranging , Parallel Group , Phase II Study Assess Efficacy , Safety/Tolerability , Pharmacokinetics Thrombopoietin Receptor Agonist , SB-497115-GR , Administered 30 , 50 , 75 mg Once Daily 12 week Subjects Chronic Hepatitis C-Related Thrombocytopenia Potential Candidates Antiviral Treatment Pegylated Interferon Ribavirin .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion criterion : Chronic low platelet count 20,000 &lt; 70,000/µL . Prior liver biopsy indicate chronic hepatitis within previous 5 year radiographic evidence cirrhosis / endoscopic evidence nonbleeding esophageal gastric varix . Exclusion criterion : History heart attack abnormal heart function . History thrombosis within 1 year . History alcohol drug abuse dependence within 1 year . Use aspirin , aspirincontaining compound , salicylate , antacid . History HIV infection active infection Hepatitis B C. Females pregnant . Patients use nonsteroidal antiinflammatory drug study within 3 week prior start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>thrombopoietin</keyword>
	<keyword>platelet</keyword>
	<keyword>Hepatitis C-related thrombocytopenia</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>